+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 55Years
All Genders
ID06111612

Intensive Stem Cell Transplant Conditioning with Thiotepa, Busulfan, Fludarabine, and Cytarabine for Myeloid Cancers with Tumors Outside the Bone Marrow

Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2024-07-22

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an intensive conditioning regimen combining thiotepa, busulfan, fludarabine, and cytarabine for patients undergoing allogeneic hematopoietic stem cell transplantation to treat myeloid malignancies with extramedullary involvement. This single-arm, prospective phase II trial aims to assess the regimens efficacy and safety, focusing on progression-free survival and other post-transplant outcomes. The study is led by Shanghai General Hospital and targets adults aged 18 to 55 with specific myeloid tumor conditions. The treatment involves a conditioning phase starting nine days before the stem cell infusion, with thiotepa given on days -9 and -8, fludarabine and cytarabine from days -7 to -3, and busulfan from days -5 to -3. Donor stem cells are infused on day 0. After transplantation, patients will undergo bone marrow examinations on days 14 and 28, followed by regular checks every 30 days during the first year and every 60 days in the second year. Additional assessments will be performed if relapse is suspected. Participants will be closely monitored for outcomes including progression-free survival at one and two years, overall survival, incidence of acute and chronic graft-versus-host disease, relapse rates, and viral reactivation. The study includes laboratory tests, bone marrow biopsies, and regular clinical evaluations to track health status and treatment effects over time. Follow-up extends up to two years post-transplant to capture long-term outcomes and safety data.

CONDITIONS

Brief Title

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Research Team

X

Xianmin Song, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here